SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lee Philina
(Last) (First) (Middle)
C/O BLUEPRINT MEDICINES CORPORATION
45 SIDNEY STREET
(Street)
CAMBRIDGE MA 02139
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Blueprint Medicines Corp [ BPMC ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CHIEF COMMERCIAL OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
08/05/2024
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/05/2024 M 157 A $36.05 34,886 D
Common Stock 08/05/2024 M 1,042 A $51.06 35,928 D
Common Stock 08/05/2024 M 5,011 A $81.44 40,939 D
Common Stock 08/05/2024 M 4,331 A $43.15 45,270 D
Common Stock 08/05/2024 M 8,450 A $54.13 53,720 D
Common Stock 08/05/2024 M 10,572 A $61.31 64,292 D
Common Stock 08/05/2024 M 12,350 A $86.6 76,642 D
Common Stock 08/05/2024 S 41,913 D $93.19(1) 34,729 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $36.05 08/05/2024 M 157 (2) 02/16/2027 Common Stock 157 $0 0 D
Stock Option (Right to Buy) $51.06 08/05/2024 M 1,042 (3) 07/03/2027 Common Stock 1,042 $0 0 D
Stock Option (Right to Buy) $81.44 08/05/2024 M 5,011 (4) 02/16/2028 Common Stock 5,011 $0 0 D
Stock Option (Right to Buy) $43.15 08/05/2024 M 4,331 (5) 03/01/2033 Common Stock 4,331 $0 20,669 D
Stock Option (Right to Buy) $54.13 08/05/2024 M 8,450 (6) 03/01/2030 Common Stock 8,450 $0 0 D
Stock Option (Right to Buy) $61.31 08/05/2024 M 10,572 (7) 03/01/2032 Common Stock 10,572 $0 6,928 D
Stock Option (Right to Buy) $86.6 08/05/2024 M 12,350 (8) 03/01/2029 Common Stock 12,350 $0 0 D
Explanation of Responses:
1. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $93.00 to $93.835 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
2. This option was granted on February 16, 2017 and is fully vested as of the transaction date.
3. This option was granted on July 3, 2017 and is fully vested as of the transaction date.
4. This option was granted on February 16, 2018 and is fully vested as of the transaction date.
5. This option was granted on March 1, 2023. This option vested with respect to 1/48th of the shares underlying the option on April 1, 2023 and as to an additional 1/48th of the shares underlying the option each month thereafter.
6. This option was granted on March 1, 2020 and is fully vested as of the transaction date.
7. This option was granted on March 1, 2022. This option vested with respect to 1/48th of the shares underlying the option on April 1, 2022 and as to an additional 1/48th of the shares underlying the option each month thereafter.
8. This option was granted on March 1, 2019 and is fully vested as of the transaction date.
/s/ Melissa Masse, Attorney-in-Fact 08/07/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Blueprint Medicines (NASDAQ:BPMC)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024 Haga Click aquí para más Gráficas Blueprint Medicines.
Blueprint Medicines (NASDAQ:BPMC)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024 Haga Click aquí para más Gráficas Blueprint Medicines.